HER2 Targeted Therapies Market Global Report 2026

The HER2 targeted therapies market size has grown strongly in recent years. It will grow from $10.84 billion in 2025 to $11.75 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to rising incidence of breast and gastric cancer cases, increasing uptake of monoclonal antibody treatments such as trastuzumab, expanding awareness of targeted cancer therapy approaches, development of oncology care infrastructure in hospitals, and growing activity in clinical trials focused on HER2-positive cancers.

The HER2 targeted therapies market size is expected to see strong growth in the next few years. It will grow to $16.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing adoption of precision oncology and biomarker-based testing, rising development of advanced next-generation antibody drug conjugate (ADC) therapies, broader implementation of personalized cancer treatment protocols, expanding investment inflows into biotechnology and biologics production capabilities, and a growing number of regulatory approvals for targeted oncology therapeutics. Key trends during the forecast period include the widening application of antibody drug conjugates in HER2-positive cancer indications, increasing uptake of biosimilar HER2-targeted treatment options, greater utilization of combination therapies involving chemotherapy and immunotherapy, rapid advancement of next-generation tyrosine kinase inhibitors, and the evolution of biomarker-guided personalized oncology care pathways.

The growing adoption of personalized medicine is expected to propel the growth of the HER2-targeted therapies market going forward. Personalized medicine refers to a medical approach that tailors treatment strategies based on an individual patient’s genetic profile, biomarker expression, and specific disease characteristics to improve therapeutic outcomes and minimize adverse effects. The growing adoption of personalized medicine is increasing due to advancements in genomic and biomarker testing, enabling more precise and effective treatments tailored to individual patient profiles while reducing adverse effects. HER2-targeted therapies support personalized medicine adoption by providing highly specific treatment options for patients with HER2-positive cancers, improving treatment effectiveness and enabling more precise disease management. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six approvals in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the HER2-targeted therapies market.

Leading companies operating in the HER2-targeted therapies market are focusing on developing advanced therapies, such as HER2-mutant advanced non-small cell lung cancer targeted therapy, to improve clinical outcomes for patients with HER2-mutant cancers. HER2-mutant advanced non-small cell lung cancer targeted therapy refers to precision treatments that specifically target HER2 gene mutations in advanced NSCLC to improve treatment response and control tumor progression with greater accuracy. For example, in February 2026, Boehringer Ingelheim, a Germany-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for HERNEXEOS (zongertinib), the first targeted therapy approved as an initial treatment option for adults with HER2-mutant advanced non-small cell lung cancer (NSCLC). HERNEXEOS is an orally administered, irreversible HER2-selective tyrosine kinase inhibitor designed to specifically target HER2 (ERBB2) mutations while minimizing wild-type EGFR-related toxicities. The therapy demonstrated a 76% objective response rate in the Beamion LUNG-1 clinical trial and offers once-daily oral administration, improved tolerability, and enhanced precision treatment for patients with unresectable or metastatic HER2-mutant NSCLC.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen, Inc. for an overall enterprise value of approximately $43 billion. Through this acquisition, Pfizer aimed to strengthen its oncology portfolio by integrating Seagen’s leading antibody-drug conjugate (ADC) platform and its HER2-targeted ADC therapies, including assets active in both HER2-positive and HER2-low cancers, into Pfizer’s global research, development, and commercial infrastructure. Seagen, Inc. is a US-based biotechnology company specializing in antibody-drug conjugate therapies for solid tumors and hematologic cancers, with a core pipeline including HER2-targeted ADC candidates.

Major companies operating in the HER2 targeted therapies market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Novartis AG, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Daiichi Sankyo Company Limited, Celltrion Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Biocon Biopharmaceuticals Pvt. Ltd., Shanghai Henlius Biotech Inc., RemeGen Co. Ltd., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Alteogen Inc., Dizal Pharmaceutical Co. Ltd., Mersana Therapeutics Inc., BioAtla Inc.

North America was the dominant region in the HER2 targeted therapies market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in HER2 targeted therapies report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the HER2 targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The HER2 targeted therapies market consists of sales of margetuximab, tucatinib, neratinib, and pyrotinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The HER2 targeted therapies market research report is one of a series of new reports that provides HER2 targeted therapies market statistics, including HER2 targeted therapies industry global market size, regional shares, competitors with a HER2 targeted therapies market share, detailed HER2 targeted therapies market segments, market trends and opportunities, and any further data you may need to thrive in the HER2 targeted therapies industry. This HER2 targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.